Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Conditions

• Atypical Teratoid/Rhabdoid Tumor
• DIPG Brain Tumor
• Diffuse Intrinsic Pontine Glioma
• Embryonal Tumor With Multilayered Rosettes
• Ewing Sarcoma
• Neuroblastoma
• Osteosarcoma

Eligibility Criteria

Sex

ALL

Age

N/A - 21 Years

Healthy Volunteers

Not accepted

Interventions

• Eflornithine (DFMO) — DRUG
  Oral DFMO capsules
• AMXT 1501 Dicaprate — DRUG
  Capsule

Study Details

The purpose of this study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (DFMO). An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any other regulatory authorities around the world for use alone or in combination with any drug, for the condition or illness it is being used to treat. The goals of this part of the study are: * Establish a recommended dose of AMXT 1501 in combination with DFMO * Test the safety and tolerability of AMXT 1501 in combination with DFMO * To determine the activity of study treatments chosen based on: * How each subject responds to the study treatment * How long a subject lives without their disease returning/progressing

Key Dates

Start date

May 13, 2026

Status verified

Jun 2026

Primary completion

May 31, 2033

Completion

May 31, 2035

Study Design

Enrollment

289 participants (estimated)

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Arms

• Experimental: Phase I- AYA Cohort
  The initial phase I will be an AYA (adolescents and young adult) cohort that will be for subjects ≥12 years of age at enrollment in a standard 3+3 design in which groups of 3 subjects per cohort will be treated and assessed. Subjects will receive up to twenty-four (24), 28-day cycles of AMXT 1501 combined with DFMO. Subjects will receive oral AMXT 1501 at a starting dose of 350 mg/m2 BID each day. The dose escalation scheme for subsequent groups and modifications for dose limiting toxicities (DLT) are detailed in the protocol.
• Experimental: Phase I- Pediatric Cohort
  The second phase I will be a pediatric cohort that will be for subjects \< 12 years of age at enrollment in a standard 3+3 design in which groups of 3 subjects per cohort will be treated and assessed. Subjects will receive up to twenty-four (24), 28-day cycles of AMXT 1501 combined with DFMO. Subjects will receive oral AMXT 1501 at a starting dose of 350 mg/m2 BID each day. The dose escalation scheme for subsequent groups and modifications for dose limiting toxicities (DLT) are detailed in the protocol.
• Experimental: Phase II- Arm A: AMXT 1501 + DFMO
  In this portion of the study, cohort 1 will be randomized to either receive Arm A: oral AMXT 1501 at the recommended phase 2 dose (RP2D) found in the Phase I along with oral DFMO at the RP2D found in the Phase I on each day of study or Arm B: oral DFMO alone at the recommended phase 2 dose (RP2D) found in the Phase I. Subjects will receive up to twenty-four (24), 28-day cycles of their assigned treatment. Cohorts 2 (ETMR/ATRT), 3 (DIPG), and 4 (Sarcomas) will automatically be assigned to Arm A with AMXT 1501 in combination with DFMO. Subjects in cohort 1 who progress on DFMO alone (and have met the primary PFS endpoint) may cross over to AMXT 1501+DFMO.
• Active Comparator: Phase II- Arm B: DFMO Alone
  In this portion of the study, cohort 1 will be randomized to either receive Arm A: oral AMXT 1501 at the recommended phase 2 dose (RP2D) found in the Phase I along with oral DFMO at the RP2D found in the Phase I on each day of study or Arm B: oral DFMO alone at the recommended phase 2 dose (RP2D) found in the Phase I. Subjects will receive up to twenty-four (24), 28-day cycles of their assigned treatment. Cohorts 2 (ETMR/ATRT), 3 (DIPG), and 4 (Sarcomas) will automatically be assigned to Arm A with AMXT 1501 in combination with DFMO. Subjects in cohort 1 who progress on DFMO alone (and have met the primary PFS endpoint) may cross over to AMXT 1501+DFMO.

Primary Outcome Measure

Phase I- Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 28 days ]

Central Contacts

• BCC Enroll
  7175310003
  [email protected]

Locations (10)

Find similar trials in Birmingham, AL

Related Studies

• Clinical Orthopaedic Data Bank (Acute and Chronic)
  Recruiting · University of Florida · Gainesville, Florida
• Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
  Recruiting · National Cancer Institute (NCI) · Washington D.C., District of Columbia
• Neuroblastoma Biology Study
  Recruiting · New Approaches to Neuroblastoma Therapy Consortium · Los Angeles, California
• Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
  Recruiting · Children's Oncology Group · Birmingham, Alabama